GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abera Bioscience AB (XSAT:ABERA) » Definitions » Growth Rank

Abera Bioscience AB (XSAT:ABERA) Growth Rank : 0 (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abera Bioscience AB Growth Rank?

Abera Bioscience AB has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Abera Bioscience AB Growth Rank Related Terms

Thank you for viewing the detailed overview of Abera Bioscience AB's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Abera Bioscience AB (XSAT:ABERA) Business Description

Traded in Other Exchanges
N/A
Address
Svetsarvagen 15, Solna, SWE, SE-17141
Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.

Abera Bioscience AB (XSAT:ABERA) Headlines

No Headlines